Ieq Capital LLC Purchases 5,208 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Ieq Capital LLC raised its stake in Alnylam Pharmaceuticals by 13.4%, acquiring an additional 5,208 shares, bringing its total to 44,014 shares valued at approximately $11.9 million.
• Insider trading activity included CEO Yvonne Greenstreet selling 6,979 shares for about $3.2 million, marking an 11.04% decrease in her ownership.
• Alnylam Pharmaceuticals received positive ratings from multiple analysts, with price targets raised as high as $570, indicating a strong market outlook following a quarterly earnings beat.

Ieq Capital LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 13.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,014 shares of the biopharmaceutical company's stock after purchasing an additional 5,208 shares during the quarter. Ieq Capital LLC's holdings in Alnylam Pharmaceuticals were worth $11,885,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Caisse DE Depot ET Placement DU Quebec raised its stake in Alnylam Pharmaceuticals by 137.2% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 23,763 shares of the biopharmaceutical company's stock valued at $6,416,000 after buying an additional 13,745 shares during the last quarter. Comerica Bank raised its stake in Alnylam Pharmaceuticals by 23.3% in the first quarter. Comerica Bank now owns 17,253 shares of the biopharmaceutical company's stock valued at $4,659,000 after buying an additional 3,262 shares during the last quarter. Jump Financial LLC raised its stake in Alnylam Pharmaceuticals by 3.8% in the first quarter. Jump Financial LLC now owns 15,717 shares of the biopharmaceutical company's stock valued at $4,244,000 after buying an additional 572 shares during the last quarter. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at about $27,000. Finally, Smartleaf Asset Management LLC raised its stake in Alnylam Pharmaceuticals by 19.8% in the first quarter. Smartleaf Asset Management LLC now owns 895 shares of the biopharmaceutical company's stock valued at $240,000 after buying an additional 148 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 6,979 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the transaction, the chief executive officer directly owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This represents a 11.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,396 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $632,764.92. Following the transaction, the executive vice president directly owned 22,719 shares of the company's stock, valued at approximately $10,297,841.13. This trade represents a 5.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,531 shares of company stock worth $41,087,238 over the last quarter. 1.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several research analyst reports. Piper Sandler raised their price objective on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Wall Street Zen raised Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. BMO Capital Markets raised their target price on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the stock an "outperform" rating in a report on Tuesday, June 24th. HC Wainwright raised their target price on Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. Finally, Scotiabank raised their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $405.33.

Alnylam Pharmaceuticals Trading Up 0.7%

Shares of NASDAQ ALNY opened at $454.18 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $469.81. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The stock has a fifty day simple moving average of $369.03 and a 200-day simple moving average of $300.28. The stock has a market capitalization of $59.53 billion, a PE ratio of -183.88 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.86. The business had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.During the same period in the prior year, the firm posted ($0.13) EPS. The business's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.